InCytu is driven by a world class senior management team with over 140 years of combined experience in cell-based therapies. Their development capability and extensive industry experience has yielded

• More than 250 published scientific papers
• More than 88 filed patents
• More than of 45 completed clinical studies (ph I-IV)
  

Alfred Vasconcellos - President and CEO

Al has thirty years of experience in the health care industry, and over twenty years of experience in therapeutics, medical devices and tissue regeneration. He has reproducibly demonstrated the capability to shepherd novel technologies from creation to commercialization. Al has been CEO/Senior Manager of 6 biotechnology start-up companies and has held C-level or VP positions at 3 other life science companies including Pfizer.

Dwaine Emerich - Vice President of Research

Dwaine has had decades of proven success developing cell therapy, immune modulation and protein delivery products. He has held CSO/VP of Research positions at 3 start-up life science companies. Dwaine also holds 22 patents and has published over 200 journal articles.

Richard Berenson - Acting CFO

Richard has been CEO/COO of ten companies, CFO/Treasurer of more than five companies, and helped form InCytu to commercialize David Mooney’s technology. He has been leading organizations and developing practical, break-through strategy for more than twenty years. Rick has worked across a broad range of industries and can master new technologies and markets with speed. Rick received a JD-MBA from Harvard Business and Law Schools in 1984 and is a graduate of Harvard College.

David Mooney - Scientific Advisor

David Mooney is the Gordon McKay Professor of Bioengineering in the Harvard School of Engineering and Applied Sciences at Harvard University. His laboratory is focused on the design and synthesis of materials that define microenvironments, or niches, that regulate the fate of either transplanted cell populations or cells already resident in tissues. Dr. Mooney is a Fellow of the American Institute of the Medical and Biological Engineering, a NIH MERIT awardee, the recipient of the Clemson Award from the Society for Biomaterials, and has received the NSF CAREER award. His inventions have been licensed by eight companies for development and he is active on industrial scientific advisory boards.